Ads
related to: colorectal cancer screening- HER2+ mCRC Testing
Learn How To Test
Learn When to Test
- Dosing & Administration
View Dosing Charts
Study Dosing Information Here
- Clinical Study
Trial Design and Endpoints
Inlcusion Criteria Here
- Efficacy & Safety
Adverse Reactions Of Interest
Common Reactions Table
- HER2+ mCRC Testing
Search results
How systems could double colorectal cancer screenings
Becker's ASC Review· 2 days agoGiving patients more choice in their colorectal cancer screening options could double the number of patients who get screened, according ...
U.S. FDA advisers back approval for Guardant's blood-based cancer test
Reuters via AOL· 8 hours ago(Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday recommended for the...
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
Benzinga via Yahoo Finance· 2 days agoInc's (NASDAQ:GH) experimental blood test for colorectal cancer, suggesting it might not detect some...
U.S. FDA advisers back approval for Guardant's blood-based cancer test By Reuters
Investing.com· 7 hours agoThe panel voted seven-to-two in favor of benefits outweighing risks when using the test called...
What's Going On With Colorectal Cancer Diagnostic-Focused Guardant Health Stock On Tuesday?
Benzinga· 2 days agoHealth Inc's GH experimental blood test for colorectal cancer, suggesting it might not detect some...
Guardant colon cancer test struggles to detect non-cancerous tumors, FDA says
MedTech Dive via Yahoo Finance· 2 days agoThe Guardant test may increase compliance with colorectal cancer screening and detect the disease at...
...BioAnalytics and University College London Demonstrates Significant Improvement Over CA125 and...
WROC Rochester· 7 hours agoMercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsy for the early detection of cancer, will present data at the American Society of Clinical Oncology ...
Canaccord maintains Buy on Guardant Health stock, bullish on prospects By Investing.com
Investing.com· 2 days agoOn Wednesday, Canaccord Genuity (TSX:CF) maintained its Buy rating and $30.00 price target for...
Exact Sciences files second patent infringement case against St. Louis competitor Geneoscopy - St....
The Business Journals· 1 day agoExact Sciences Corp., the Madison, Wisconsin, developer of the stool-based Cologuard colorectal ...
Some People May Safely Extend Colonoscopy Screenings to Every 15 Years, Research Shows
Health.com· 4 days agoIn the U.S., most screening guidelines recommend people get a colonoscopy every 10 years to check...